MedTrace Logo

Evaluation of the Pharmacokinetics (PK) and Pharmacodymamics (PD) of Ganciclovir (GCV) in Premature Infants Receiving Treatment for Cytomegalorivus (CMV) Infection

NCT01602614 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 18

Last updated 2020-06-02

Study results available
· View outcomes & findings →

Summary

This is a clinical sampling study, and no study drugs will be administered under this protocol. Premature infants who receive intravenous ganciclovir as part of clinical care will be eligible for participation in this study. Intravenous ganciclovir will not be provided under this protocol.

Conditions

  • Cytomegalovirus Infections

Sponsors & Collaborators

  • University of Alabama at Birmingham

    lead OTHER

Principal Investigators

  • David Kimberlin, MD · University of Birmingham at Alabama

  • Richard Whitley, MD · University of Alabama at Birmingham

Eligibility

Min Age
1 Day
Max Age
180 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2019-03-31
Completion
2019-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01602614 on ClinicalTrials.gov